Stanley Druckenmiller
PTGX icon

Stanley Druckenmiller’s Protagonist Therapeutics PTGX Stock Holding History

Stanley Druckenmiller’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.8M Hold
159,700
– – 0.5% 44
2025
Q4 		$13.9M Hold
159,700
– – 0.31% 49
2025
Q3 		$10.6M Buy
+159,700
New +$9.08M 0.26% 57

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Stanley Druckenmiller's PTGX Position: Q1 2026 in Review

Stanley Druckenmiller held its Protagonist Therapeutics (PTGX) position steady in Q1 2026 at 159,700 shares worth $16.8M. The position accounts for 0.5% of the portfolio, ranked #44.

Stanley Druckenmiller first reported a position in PTGX in Q3 2025 and has held it in 3 quarters since. 318 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Stanley Druckenmiller held 159,700 shares of Protagonist Therapeutics worth $16.8M as of Q1 2026.
  • Stanley Druckenmiller left its Protagonist Therapeutics share count unchanged in Q1 2026.
  • Protagonist Therapeutics made up 0.5% of Stanley Druckenmiller's portfolio in Q1 2026, its #44 holding.
  • Stanley Druckenmiller first reported a position in Protagonist Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 318 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Duquesne Family Office's 13F filing for Q1 2026, filed 15 May 2026.